New hope for Tough-to-Treat lung cancer?
NCT ID NCT06016270
Summary
This study tested a new drug called hSTC810 combined with a standard chemotherapy (paclitaxel) for people with advanced small cell lung cancer that had returned or stopped responding to prior treatment. The goal was to see if this combination was safe and could help control the cancer. The trial was designed in two parts, first checking safety and then looking at how well the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seoul, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
The Catholic University of Korea St. Vincent's Hospital
Suwon, 16247, South Korea
-
Tisch Cancer Institute at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.